1.Weng SF, Kai J, Guha IN, Qureshi N. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart 2015;2:e000272.

2.Smita D, Dandekar S, Chaturvedi S. Increased serum alkaline phosphatase activity in different cardiac diseases. Int J Recent Sci Res 2018;9:24262-4.

3.Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids 2015;2015:971453.

4.Shen J, Zhang J, Wen J, Ming Q, Zhang J, Xu Y. Correlation of serum alanine aminotransferase and aspartate aminotransferase with coronary heart disease. Int J Clin Exp Med 2015;8:4399- 404.

5.Cecilia S, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up 1. Hepatology 2010;51:595-602.

6.Kasper DL, Braunwald E, Fauci H. Harrison’s Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2004. p. 1301-486.

7.Masoudkabir F, Karbalai S, Vasheghani-Farahani A, Aliabadi LL, Boroumand MA, Aiatollahzade-Esfahani F, et al. The association of liver transaminase activity with presence and severity of premature coronary artery disease. Angiology 2011;62:614-9.

8.Han X, Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost 2015;113:505-12.

9.Cagli K, Basar FN, Tok D, Turak O, Basar O. How to interpret liver function tests in heart failure patients? Turk J Gastroenterol 2015;26:197-203.